Needham & Company LLC Reaffirms Buy Rating for Hologic (NASDAQ:HOLX)

Needham & Company LLC reaffirmed their buy rating on shares of Hologic (NASDAQ:HOLX) in a research report released on Tuesday, January 9th, Marketbeat reports. The brokerage currently has a $50.00 target price on the medical equipment provider’s stock, up from their prior target price of $48.00.

Other equities analysts have also issued research reports about the stock. Evercore ISI began coverage on shares of Hologic in a research report on Wednesday, January 3rd. They set an outperform rating and a $50.00 price objective for the company. Cowen upgraded shares of Hologic from a market perform rating to an outperform rating and set a $51.00 price objective for the company in a research report on Monday, December 11th. Piper Jaffray Companies restated a buy rating and issued a $48.00 target price on shares of Hologic in a report on Thursday, November 9th. Royal Bank of Canada restated a hold rating and issued a $42.00 target price on shares of Hologic in a report on Friday, September 22nd. Finally, Zacks Investment Research upgraded shares of Hologic from a sell rating to a hold rating in a report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $48.79.

Shares of Hologic (NASDAQ:HOLX) traded down $0.54 during trading hours on Tuesday, hitting $42.04. 1,918,462 shares of the company were exchanged, compared to its average volume of 2,671,250. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. Hologic has a 12-month low of $35.76 and a 12-month high of $46.80. The company has a market capitalization of $12,153.26, a price-to-earnings ratio of 15.92, a price-to-earnings-growth ratio of 1.97 and a beta of 0.77.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The firm had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. During the same quarter in the prior year, the business earned $0.52 earnings per share. Hologic’s revenue for the quarter was up 10.5% on a year-over-year basis. equities research analysts anticipate that Hologic will post 2.18 EPS for the current year.

In other news, VP Karleen Marie Oberton sold 1,256 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total value of $49,348.24. Following the sale, the vice president now directly owns 9,406 shares in the company, valued at approximately $369,561.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elaine Ullian sold 9,282 shares of Hologic stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. Insiders sold a total of 12,099 shares of company stock worth $487,223 over the last 90 days. Company insiders own 0.79% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. RKL Wealth Management LLC boosted its stake in Hologic by 8.6% in the 4th quarter. RKL Wealth Management LLC now owns 25,951 shares of the medical equipment provider’s stock worth $1,109,000 after purchasing an additional 2,066 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its stake in Hologic by 0.5% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 368,144 shares of the medical equipment provider’s stock worth $15,738,000 after purchasing an additional 1,776 shares in the last quarter. Steinberg Global Asset Management boosted its stake in Hologic by 9.3% in the 4th quarter. Steinberg Global Asset Management now owns 25,379 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 2,168 shares in the last quarter. Everence Capital Management Inc. acquired a new stake in Hologic in the 4th quarter worth approximately $280,000. Finally, Comerica Bank boosted its stake in Hologic by 26.5% in the 4th quarter. Comerica Bank now owns 96,989 shares of the medical equipment provider’s stock worth $4,161,000 after purchasing an additional 20,341 shares in the last quarter. Institutional investors own 97.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/04/hologic-holx-stock-rating-reaffirmed-by-needham-company-llc.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply